Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
Top Cited Papers
- 12 December 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (12), 3151-3158
- https://doi.org/10.1002/art.10679
Abstract
Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymphoproliferative disorders in patients treated with these agents. Relevant data in the MedWatch postmarket adverse event surveillance system run by the US Food and Drug Administration were reviewed. We identified 26 cases of lymphoproliferative disorders following treatment with etanercept (18 cases) or infliximab (8 cases). The majority of cases (81%) were non-Hodgkin's lymphomas. The interval between initiation of therapy with etanercept or infliximab and the development of lymphoma was very short (median 8 weeks). In 2 instances (1 infliximab, 1 etanercept), lymphoma regression was observed following discontinuation of anti-TNF treatment, in the absence of specific cytotoxic therapy directed toward the lymphoma. Although data from a case series such as this cannot establish a clear causal relationship between exposure to these medications and the risk of lymphoproliferative disease, the known predisposition of patients with RA and CD to lymphoma, the known excess of lymphoma in other immunosuppressed populations, and the known immunosuppressive effects of the anti-TNF drugs provide a biologic basis for concern and justification for the initiation of additional epidemiologic studies to formally evaluate this possible association.Keywords
This publication has 37 references indexed in Scilit:
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- InfliximabDrugs, 2000
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcomeBone Marrow Transplantation, 1999
- Lymphoma in Patients with Rheumatoid ArthritisDrug Safety, 1999
- Hodgkin's Disease and Lymphoproliferations Resembling Hodgkin's Disease in Patients Receiving Long-Term Low-Dose Methotrexate TherapyThe American Journal of Surgical Pathology, 1996
- Rheumatoid arthritis and cancer riskEuropean Journal of Cancer, 1996
- Immunosuppression-Associated Lymphoproliferative Disorders in Rheumatic PatientsLeukemia & Lymphoma, 1995
- Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serumArthritis & Rheumatism, 1988
- Adverse-Drug-Reaction MonitoringThe New England Journal of Medicine, 1986
- Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritisJournal of Chronic Diseases, 1978